Search Results | Blood | American Society of Hematology

1-20 of 120

2 3 4 5

Sort by

Sort Order Select

Journal Articles

TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia

Mehrnoosh Tashakori, Tapan Kadia, Sanam Loghavi, Naval Daver, Rashmi Kanagal-Shamanna, Sherry Pierce, Dawen Sui, Peng Wei, Farnoosh Khodakarami, Zhenya Tang, Mark Routbort, Carol A. Bivins, Elias J. Jabbour, L. Jeffrey Medeiros, Kapil Bhalla, Hagop M. Kantarjian, Farhad Ravandi, Joseph D. Khoury

Blood (2022) 140 (1): 58–72.

DOI: https://doi.org/10.1182/blood.2021013983

Published: 2022

Includes: Supplemental data

Journal Articles

Lenalidomide promotes the development of TP53 -mutated therapy-related myeloid neoplasms

Blood blood.2021014956.

DOI: https://doi.org/10.1182/blood.2021014956

Published: 2022

Includes: Supplemental data

Journal Articles

A Phase I Study of the Combination of Venetoclax and Azacitidine in Relapse/Refractory Higher Risk Myelodysplastic Syndrome (MDS)

Sai Prasad Prasad Desikan, Guillermo Montalban-Bravo, Maro Ohanian, Naval Daver, Musa Yilmaz, Marina Konopleva, Tapan M. Kadia, Sangeetha Venugopal, Heather Schneider, Kelly S. Chien, Rashmi Kanagal-Shamanna, Hagop Kantarjian, Guillermo Garcia-Manero

Blood (2021) 138 (Supplement 1): 3704.

DOI: https://doi.org/10.1182/blood-2021-153170

Published: 2021

Journal Articles

Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): Focus on Long-Term MRD Results

Blood (2021) 138 (Supplement 1): 3720.

DOI: https://doi.org/10.1182/blood-2021-154454

Published: 2021

Journal Articles

Inhibition of MDM2 Improves the Therapeutic Effect of Hypomethylating Agents in Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)

Yue Wei, Hong Zheng, Pamela Lockyer, Naran Bao, Faezeh Darbaniyan, Ziyi Li, Rashmi Kanagal-Shamanna, Kelly A. Soltysiak, Hui Yang, Irene Ganan-Gomez, Kim-Anh Do, Simona Colla, Kelly S. Chien, Guillermo Montalban-Bravo, Naval Daver, Guillermo Garcia-Manero

Blood (2021) 138 (Supplement 1): 3664.

DOI: https://doi.org/10.1182/blood-2021-150811

Published: 2021

Journal Articles

Initial Results of Phase I/II Study of Azacitidine in Combination with Quizartinib for Patients with Myelodysplastic Syndrome and Myelodysplastic/Myeloproliferative Neoplasm with FLT3 or CBL Mutations

Tareq Abuasab, Elias J. Jabbour, Nicholas J. Short, Marina Konopleva, Kelly S. Chien, Shehab Fareed Mohamed, Naval Daver, Rashmi Kanagal-Shamanna, Hagop Kantarjian, Guillermo Garcia-Manero, Guillermo Montalban-Bravo

Blood (2021) 138 (Supplement 1): 1536.

DOI: https://doi.org/10.1182/blood-2021-153189

Published: 2021

Journal Articles

Ibrutinib Plus Rituximab and Venetoclax (IRV) Followed By Risk-Stratified Observation or Short Course R-Hypercvad/MTX in Young Patients with Previously Untreated Mantle Cell Lymphoma - Phase-II Window-2 Clinical Trial

Blood (2021) 138 (Supplement 1): 3525.

DOI: https://doi.org/10.1182/blood-2021-153390

Published: 2021

Journal Articles

Outcomes of Patients with Chronic Myelomonocytic Leukemia (CMML) Treated with Hypomethylating Agents

Sangeetha Venugopal, Kelly S. Chien, Danielle Hammond, Rashmi Kanagal-Shamanna, Koji Sasaki, Tapan M. Kadia, Courtney D. DiNardo, Marina Konopleva, Naval Daver, Farhad Ravandi, Naveen Pemmaraju, Nicholas J. Short, Ghayas C. Issa, Koichi Takahashi, Zeev E. Estrov, Sherry A. Pierce, Hagop Kantarjian, Guillermo Garcia-Manero, Guillermo Montalban-Bravo

Blood (2021) 138 (Supplement 1): 2613.

DOI: https://doi.org/10.1182/blood-2021-153475

Published: 2021

Journal Articles

Venetoclax, Obinutuzumab and Atezolizumab (PD-L1 Checkpoint Inhibitor) for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)

Blood (2021) 138 (Supplement 1): 2626.

DOI: https://doi.org/10.1182/blood-2021-154195

Published: 2021

Journal Articles

Single-Cell RNA Sequencing Analysis Reveals Mechanisms of Initiation and Progression in Chronic Myelomonocytic Leukemia

Guillermo Montalban-Bravo, Feiyang Ma, Irene Ganan-Gomez, Rashmi Kanagal-Shamanna, Vera Adema, Yue Wei, Kelly S. Chien, Natthakan Thongon, Hui Yang, Carlos E. Bueso-Ramos, Hagop Kantarjian, Guillermo Garcia-Manero, Simona Colla

Blood (2021) 138 (Supplement 1): 2588.

DOI: https://doi.org/10.1182/blood-2021-151340

Published: 2021

Journal Articles

Increased hnRNP K Expression Impacts Myelopoiesis By Altering RUNX1 Splicing

Sean M Post, Marisa J Aitken, Prerna Malaney, Xiaorui Zhang, Todd Link, Rodrigo Jacamo, Rashmi Kanagal-Shamanna, Carlos E. Bueso-Ramos

Blood (2021) 138 (Supplement 1): 3317.

DOI: https://doi.org/10.1182/blood-2021-154149

Published: 2021

Journal Articles

A Phase I/II Study of Venetoclax in Combination with 5-Azacytidine in Treatment-Naïve and Relapsed/Refractory High-Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)

Blood (2021) 138 (Supplement 1): 535.

DOI: https://doi.org/10.1182/blood-2021-153086

Published: 2021

Journal Articles

Venetoclax, Obinutuzumab and Atezolizumab (PD-L1 Checkpoint Inhibitor) for Treatment for Patients with Richter Transformation

Blood (2021) 138 (Supplement 1): 1550.

DOI: https://doi.org/10.1182/blood-2021-154279

Published: 2021

Journal Articles

Retrospective Single-Institution Analysis of Patients with Chronic Lymphocytic Leukemia with TP53 alterations Treated First-Line with Bruton's Tyrosine Kinase Inhibitor-Based Therapy

Hua-Jay J. Cherng, Raamis Khwaja, Rashmi Kanagal-Shamanna, Jan A. Burger, Philip A. Thompson, Alessandra Ferrajoli, Zeev E. Estrov, Koji Sasaki, Deepa Sampath, Guilin Tang, Xuemei Wang, Hagop Kantarjian, Michael J. Keating, William G. Wierda, Nitin Jain

Blood (2021) 138 (Supplement 1): 394.

DOI: https://doi.org/10.1182/blood-2021-146432

Published: 2021

Journal Articles

A Phase I/II Study of Venetoclax in Combination with ASTX727 (cedazuridine/decitabine) in Treatment‐Naïve High‐Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)

Sangeetha Venugopal, Hagop Kantarjian, Abhishek Maiti, Nicholas J. Short, Guillermo Montalban-Bravo, Yesid Alvarado, Kelly S. Chien, Rashmi Kanagal-Shamanna, Naveen Pemmaraju, Naval Daver, Tapan M. Kadia, Gautam Borthakur, Elias J. Jabbour, Guillermo Garcia-Manero

Blood (2021) 138 (Supplement 1): 245.

DOI: https://doi.org/10.1182/blood-2021-153657

Published: 2021

Journal Articles

Transcriptomic Signitures of Azacitidine (AZA) and Decitabine (DAC) Resistance in MDS and CMML

Faezeh Darbaniyan, Caleb Class, Guillermo Montalban-Bravo, Rashmi Kanagal-Shamanna, Marcos Estecio, Yue Lu, Kelly A. Soltysiak, Kelly S. Chien, Hui Yang, Koji Sasaki, Irene Ganan-Gomez, Simona Colla, Kim-Anh Do, Guillermo Garcia-Manero, Yue Wei

Blood (2021) 138 (Supplement 1): 4652.

DOI: https://doi.org/10.1182/blood-2021-153698

Published: 2021

Journal Articles

Assessment of Immunoglobulin Heavy Chain Variable Region ( IGHV ) Mutation Status with a Next-Generation Sequencing (NGS) Immunosequencing Assay for Measurable Residual Disease (MRD)

Lik Wee Lee, Travers Ching, Bryan Howie, Keyur P. Patel, Philip A. Thompson, Nitin Jain, Alessandra Ferrajoli, Zeev E. Estrov, Jan A. Burger, Michael J. Keating, Rashmi Kanagal-Shamanna, William G. Wierda, Lanny R. Kirsch

Blood (2021) 138 (Supplement 1): 4676.

DOI: https://doi.org/10.1182/blood-2021-146611

Published: 2021

Journal Articles

Clinical Outcomes of Patients with Newly Diagnosed Myelodysplastic Syndrome with MLL Aberrations

Maria Siddiqui, Ghayas C. Issa, Koji Sasaki, Guillermo Montalban-Bravo, Kelly S. Chien, Elias J. Jabbour, Carlos E. Bueso-Ramos, Rashmi Kanagal-Shamanna, Hagop Kantarjian, Guillermo Garcia-Manero

Blood (2021) 138 (Supplement 1): 4673.

DOI: https://doi.org/10.1182/blood-2021-151670

Published: 2021

Journal Articles

High-Throughput Characterization of Cytogenomic Heterogeneity of MDS Using High-Resolution Optical Genome Mapping

Hui Yang, Guillermo Garcia-Manero, Guillermo Montalban-Bravo, Kelly S. Chien, Awdesh Kalia, Zhenya Tang, Yue Wei, Manjunath Nimmakayalu, Diana Rush, Saradhi Mallampati, Hagop Kantarjian, Rajyalakshmi Luthra, L. Jeffrey Medeiros, Rashmi Kanagal-Shamanna

Blood (2021) 138 (Supplement 1): 105.

DOI: https://doi.org/10.1182/blood-2021-154005

Published: 2021

Journal Articles

Expert Curation of Somatic FLT3 Variants By the Clingen Somatic Hematologic Cancer Taskforce (ClinGen HCT)

Blood (2021) 138 (Supplement 1): 4387.

DOI: https://doi.org/10.1182/blood-2021-153546

Published: 2021

2 3 4 5

NARROW

TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia

Lenalidomide promotes the development of TP53 -mutated therapy-related myeloid neoplasms

A Phase I Study of the Combination of Venetoclax and Azacitidine in Relapse/Refractory Higher Risk Myelodysplastic Syndrome (MDS)

Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): Focus on Long-Term MRD Results

Inhibition of MDM2 Improves the Therapeutic Effect of Hypomethylating Agents in Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)

Initial Results of Phase I/II Study of Azacitidine in Combination with Quizartinib for Patients with Myelodysplastic Syndrome and Myelodysplastic/Myeloproliferative Neoplasm with FLT3 or CBL Mutations

Ibrutinib Plus Rituximab and Venetoclax (IRV) Followed By Risk-Stratified Observation or Short Course R-Hypercvad/MTX in Young Patients with Previously Untreated Mantle Cell Lymphoma - Phase-II Window-2 Clinical Trial

Outcomes of Patients with Chronic Myelomonocytic Leukemia (CMML) Treated with Hypomethylating Agents

Venetoclax, Obinutuzumab and Atezolizumab (PD-L1 Checkpoint Inhibitor) for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)

Single-Cell RNA Sequencing Analysis Reveals Mechanisms of Initiation and Progression in Chronic Myelomonocytic Leukemia

Increased hnRNP K Expression Impacts Myelopoiesis By Altering RUNX1 Splicing

A Phase I/II Study of Venetoclax in Combination with 5-Azacytidine in Treatment-Naïve and Relapsed/Refractory High-Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)

Venetoclax, Obinutuzumab and Atezolizumab (PD-L1 Checkpoint Inhibitor) for Treatment for Patients with Richter Transformation

Retrospective Single-Institution Analysis of Patients with Chronic Lymphocytic Leukemia with TP53 alterations Treated First-Line with Bruton's Tyrosine Kinase Inhibitor-Based Therapy

A Phase I/II Study of Venetoclax in Combination with ASTX727 (cedazuridine/decitabine) in Treatment‐Naïve High‐Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)

Transcriptomic Signitures of Azacitidine (AZA) and Decitabine (DAC) Resistance in MDS and CMML

Assessment of Immunoglobulin Heavy Chain Variable Region ( IGHV ) Mutation Status with a Next-Generation Sequencing (NGS) Immunosequencing Assay for Measurable Residual Disease (MRD)

Clinical Outcomes of Patients with Newly Diagnosed Myelodysplastic Syndrome with MLL Aberrations

High-Throughput Characterization of Cytogenomic Heterogeneity of MDS Using High-Resolution Optical Genome Mapping

Expert Curation of Somatic FLT3 Variants By the Clingen Somatic Hematologic Cancer Taskforce (ClinGen HCT)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only